Yes, Gottlieb’s in there twice; things get complicated when an agency starts to lose credibility.
The US Department of Health and Human Services – the overseer of the Food and Drug Administration and 27 other agencies and offices – is pushing back on suggestions that HHS secretary Alex Azar’s recent move to exert control over regulations was a power play aimed at the FDA.
The effort is part of a larger struggle over FDA’s reputation, with former commissioner Scott Gottlieb playing multiple roles in...
Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
